NO20072642L - Use of androgens to reduce the likelihood of acquiring or to treat skin aging - Google Patents

Use of androgens to reduce the likelihood of acquiring or to treat skin aging

Info

Publication number
NO20072642L
NO20072642L NO20072642A NO20072642A NO20072642L NO 20072642 L NO20072642 L NO 20072642L NO 20072642 A NO20072642 A NO 20072642A NO 20072642 A NO20072642 A NO 20072642A NO 20072642 L NO20072642 L NO 20072642L
Authority
NO
Norway
Prior art keywords
likelihood
acquiring
loss
androgens
reduce
Prior art date
Application number
NO20072642A
Other languages
English (en)
Inventor
Fernand Labrie
Mohamed El-Alfy
Lamia Azzi
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of NO20072642L publication Critical patent/NO20072642L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Det beskrives nye metoder for behandling eller redusering av sannsynligheten for å erverve hudsykdommer på grunn av aldersrelatert androgenmangel og særlig hudatrofi, tap av kollagen, tap av elastiske fibre, tap av bindevev, cellulitt samt dannelse av rynker. Problemet gjelder mottakelige, varmblodige dyr inkludert mennesker og involverer administrering av et androgen og/eller en kjønnssteroidforløper. Det beskrives videre farmasøytiske preparater for avlevering av aktive bestanddeler som er nyttige ifølge oppfinnelsen.
NO20072642A 2004-11-01 2007-05-23 Use of androgens to reduce the likelihood of acquiring or to treat skin aging NO20072642L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62411204P 2004-11-01 2004-11-01
PCT/CA2005/001652 WO2006047859A1 (en) 2004-11-01 2005-10-31 Use of androgens to reduce the likelihood of acquiring or to treat skin aging

Publications (1)

Publication Number Publication Date
NO20072642L true NO20072642L (no) 2007-07-30

Family

ID=36318842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072642A NO20072642L (no) 2004-11-01 2007-05-23 Use of androgens to reduce the likelihood of acquiring or to treat skin aging

Country Status (20)

Country Link
US (1) US20060178352A1 (no)
EP (1) EP1807062A4 (no)
JP (1) JP2008517952A (no)
KR (1) KR20070073964A (no)
CN (1) CN101094676A (no)
AP (1) AP2007003982A0 (no)
AU (1) AU2005301035A1 (no)
BR (1) BRPI0517950A (no)
CA (1) CA2585666A1 (no)
EA (1) EA200700983A1 (no)
GE (1) GEP20094833B (no)
HR (1) HRP20070183A2 (no)
IL (1) IL182844A0 (no)
MA (1) MA29220B1 (no)
MX (1) MX2007005098A (no)
NO (1) NO20072642L (no)
RS (1) RS20070185A (no)
TN (1) TNSN07163A1 (no)
WO (1) WO2006047859A1 (no)
ZA (1) ZA200703531B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
CN101461294B (zh) 2006-06-01 2011-05-18 松下电器产业株式会社 洗衣机用无刷电动机以及搭载其的洗衣机
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
DE112014004733A5 (de) * 2013-10-15 2016-07-14 Chelac Holding Gmbh Steroid-Carbonsäureester, Zusammensetzungen, enthaltend Steroid-Carbonsäureester und Verwendung dieser bei lokal topischer Applikation für kosmetische oder dermatologische Zwecke
RU2699674C1 (ru) * 2015-09-30 2019-09-09 Фуджифилм Корпорэйшн Композиция для чрескожной абсорбции
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL190146A (no) * 1953-08-26
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
NZ536787A (en) * 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy

Also Published As

Publication number Publication date
HRP20070183A2 (en) 2007-08-31
EA200700983A1 (ru) 2008-04-28
AP2007003982A0 (en) 2007-06-30
EP1807062A1 (en) 2007-07-18
CA2585666A1 (en) 2006-05-11
EP1807062A4 (en) 2009-06-03
AU2005301035A1 (en) 2006-05-11
TNSN07163A1 (en) 2008-11-21
GEP20094833B (en) 2009-11-25
WO2006047859A1 (en) 2006-05-11
IL182844A0 (en) 2007-09-20
CN101094676A (zh) 2007-12-26
KR20070073964A (ko) 2007-07-10
US20060178352A1 (en) 2006-08-10
BRPI0517950A (pt) 2008-10-21
JP2008517952A (ja) 2008-05-29
MX2007005098A (es) 2008-01-16
MA29220B1 (fr) 2008-02-01
RS20070185A (en) 2008-09-29
ZA200703531B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20072642L (no) Use of androgens to reduce the likelihood of acquiring or to treat skin aging
MX2007009368A (es) Metodo para estimular la sintesis de colagena y/o expresion de factor de crecimiento de queratinocitos.
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
DE502005001762D1 (de) Verwendung von N-Hydroxyalkyl-O-benzylchitosanen zur Haarbehandlung
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
TW200509956A (en) Compositions and methods for treatment of rosacea
DE60135755D1 (de) Verbindungen und methoden zur behandlung von hautverletzungen
SG196769A1 (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
HK1082203A1 (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
EA201290698A1 (ru) Композиция, содержащая экстракт венериной мухоловки для косметической обработки
MX2011010781A (es) Una crema medicinal hecha con sulfadiazina de plata y quitosano y un proceso para hacerla.
DE60103894D1 (de) Sprühfähige wundversorgungszusammensetzung
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
Lou et al. Analysis of the effectiveness of basic fibroblast growth factor treatment on traumatic perforation of the tympanic membrane at different time points
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
UA88175C2 (ru) Способ косметической обработки стареющей кожи при помощи местного применения композиции, которая содержит циклогексанмоно-, -ди- или -триолы или циклогексилметан- или -этан-, или -пропанолы
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
RS20070399A (en) Device for the hot-dip coating of a metal strip
US10874883B2 (en) Product for treating the skin and mucous membranes, and relative method of preparation
AU2020327022A8 (en) Method of treating cancer
EA202191211A1 (ru) Композиции и способы для обработки транзиторных биопленок
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
Truswell Combining fractional carbon-dioxide laser resurfacing with face-lift surgery

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application